Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Its Subsidiary Regen BioPharma, Inc.
06 March 2014 - 7:53PM
Marketwired
Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to
Receive Shares in Its Subsidiary Regen BioPharma, Inc.
Distribution Set at 1 Regen BioPharma Common Share for Every 147
Bio-Matrix Scientific Group Inc. Shares -- Record Date Is March 18,
2014
SAN DIEGO, CA--(Marketwired - Mar 6, 2014) - Bio-Matrix
Scientific Group Inc. (OTCQB: BMSN) announced March 18, 2014 as the
record date established by BMSN for determining shareholders
eligible to receive a special dividend consisting of a pro rata
share of 20,000,000 Regen BioPharma common shares ("Special
Dividend"). All shareholders of record as of the Record Date shall
receive the Special Dividend. It is anticipated that shareholders
of record shall receive one share of Regen Biopharma, Inc. for
every 147 shares of BMSN. The 147 may consist of common, any series
of preferred, or any combination thereof.
Payment of the Special
Dividend is contingent on effectiveness of a registration statement
filed with the United States Securities and Exchange Commission
(SEC) registering the shares to be distributed under the Securities
Act of 1933 as well as completion of review and processing of the
notification of the Special Dividend provided by BMSN to the
Financial Industry Regulatory Authority (FINRA) pursuant to federal
law.
Currently there are 51,910,000
common shares issued and outstanding. Bio-Matrix Scientific Group
Inc. owns 50,000,000 of these issued common shares. Bio-Matrix
plans on distributing 20,000,000 of its shares to Bio-Matrix
shareholders of record on March 18, 2014 (with a pay date subject
to SEC and FINRA approvals). After the distribution of 20,000,000
shares, Bio-Matrix Scientific Group will still be a majority owner
of Regen BioPharma, as it will own 30,000,000 common Regen
BioPharma Inc. shares.
About Regen BioPharma: Regen BioPharma, Inc., a
subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a
biotechnology company focused on identifying undervalued
regenerative medicine applications in the stem cell space and
rapidly advancing these technologies through pre-clinical and Phase
I/ II clinical trials. Currently the Company is focused on
developing treatments for Aplastic Anemia and a gene silencing
therapy for treating cancer. For more information refer to the
company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking
statements. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to
which forward looking statements are subject include, but are not
limited to, the effect of government regulation, competition and
other material risks.
Contact: Bio-Matrix Scientific Group, Inc. and Regen BioPharma
Inc. David R. Koos, PhD Chairman & Chief Executive Officer
619-702-1404
www.regenbiopharma.com